TRuE-V Long-Term Extension Study Design


The study design for the TRuE-V long-term extension study is discussed.

In this segment, the discussion between Gary Owens, M.D., and David Rosmarin, M.D., revolves around the design and findings of the TRuE-V long-term extension study for vitiligo. The study segregates patients into two cohorts based on their treatment response. Cohort A consists of highly responsive individuals, randomly assigned either to continue medication or switch to the vehicle arm. Cohort B focuses on patients with less optimal results, exploring the possibility of additional benefits with continued use of ruxolitinib and calcineurin inhibitors. The experts emphasize the study’s significance in addressing questions related to the necessity of indefinite

medication for patients showing a response and the potential for delayed response in those initially less responsive. The discussion highlights the importance of both study arms in understanding vitiligo treatment outcomes and generating valuable insights for the future management of the disease.

Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.

Recent Videos
Video 5 - "Obstacles in Adapting Diabetes Technology to Individual Needs" - 1 KOL is featured
Video 4 - "The Impact of Continuous Glucose Monitors & Digital Solutions on Diabetes Care"
Video 3 - "The Pivotal Role of Patient Engagement and Education in Achieving Optimal Diabetes Outcomes"
Video 2 - "Addressing Coexisting Conditions: Keys to Comprehensive Diabetes Care"
Video 1 - "The Influence of Social Determinants of Health on Diabetes Care and Outcomes"
Video 4 - "Enhancing Patient Understanding and Treatment Adherence"
Video 2 - "Overview of Treatments for Atopic Dermatitis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.